U.S. markets open in 4 hours 12 minutes
  • S&P Futures

    3,935.25
    -5.25 (-0.13%)
     
  • Dow Futures

    31,818.00
    -62.00 (-0.19%)
     
  • Nasdaq Futures

    11,765.25
    -5.75 (-0.05%)
     
  • Russell 2000 Futures

    1,762.50
    -1.90 (-0.11%)
     
  • Crude Oil

    110.86
    +1.09 (+0.99%)
     
  • Gold

    1,855.50
    -9.90 (-0.53%)
     
  • Silver

    21.89
    -0.17 (-0.78%)
     
  • EUR/USD

    1.0667
    -0.0071 (-0.66%)
     
  • 10-Yr Bond

    2.7600
    0.0000 (0.00%)
     
  • Vix

    29.76
    +1.28 (+4.49%)
     
  • GBP/USD

    1.2506
    -0.0026 (-0.21%)
     
  • USD/JPY

    127.0690
    +0.2400 (+0.19%)
     
  • BTC-USD

    29,727.15
    +427.73 (+1.46%)
     
  • CMC Crypto 200

    661.62
    +5.79 (+0.88%)
     
  • FTSE 100

    7,506.05
    +21.70 (+0.29%)
     
  • Nikkei 225

    26,677.80
    -70.34 (-0.26%)
     

Outlook Therapeutics to Present at the H.C. Wainwright BioConnect Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

ISELIN, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary III, President and Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022.

A video webcast of the fireside chat will be available for viewing on-demand beginning Monday, January 10, 2022, at 7:00 AM ET for those registered for the conference and will be accessible on the Events page of the Investors section of the Outlook Therapeutics website, outlooktherapeutics.com.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:
Media Inquiries:
Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com